Merrimack Pharma (MACK) Tops Q3 EPS by 148c

Merrimack Pharma (NASDAQ: MACK) reported Q3 EPS of ($0.40), $1.48 better than the analyst estimate of ($1.88). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c